Oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) will be announcing earnings results this Tuesday before the bell. Here’s what investors should know.
NeoGenomics beat analysts’ revenue expectations by 2.1% last quarter, reporting revenues of $187.8 million, up 11.9% year on year. It was a strong quarter for the company, with EPS in line with analysts’ estimates and a solid beat of analysts’ revenue estimates.
Is NeoGenomics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting NeoGenomics’s revenue to grow 9.5% year on year to $188.3 million, slowing from the 10.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.04 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. NeoGenomics has missed Wall Street’s revenue estimates three times over the last two years.
Looking at NeoGenomics’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 7.1%, beating analysts’ expectations by 1.9%, and DaVita reported revenues up 9.9%, topping estimates by 3.2%. Quest traded up 9.4% following the results while DaVita was also up 21.2%.
Read our full analysis of Quest’s results here and DaVita’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. NeoGenomics is down 10% during the same time and is heading into earnings with an average analyst price target of $14.56 (compared to the current share price of $11.39).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
